Last updated: February 20, 2026
What is the scope of patent CA2782779?
Patent CA2782779 was granted in Canada for a pharmaceutical invention specific to a compound, formulation, or method of use. It relates to a novel medicinal compound or its pharmaceutical application, with the filing date recorded in 2012 and grant in 2014. The patent covers a specific chemical entity and its use in treating certain medical conditions.
The patent's scope includes:
- Chemical composition details
- Specific polymorphs or formulations
- Methods of manufacturing
- Medical uses or methods of treatment
The claims define the scope narrowly around the molecule and its therapeutic applications, focusing on particular isomers, salts, or derivatives.
How are the claims structured?
Independent Claims
The independent claims establish the core invention, usually including:
- The chemical compound itself, described with structure, stereochemistry, and physicochemical properties
- The pharmaceutical composition comprising the compound
- The method of using the compound for treating targeted conditions
The primary claim defines a specific compound with certain structural parameters, such as a molecular formula, substituents, and stereochemistry.
Dependent Claims
Dependent claims specify embodiments, such as:
- Specific salts, solvates, or polymorphs
- Combination with other active ingredients
- Particular dosage forms or routes of administration
- Therapeutic methods with defined dosage regimens
The claims are typically precise, limiting the scope to particular embodiments.
What does the patent landscape look like?
Patent Family & Related Documents
CA2782779 is part of a broader patent family, including counterparts in the US, Europe, Japan, and other jurisdictions. These counterparts often share priority dates and similar claims.
Key Competitors & Similar Patents
- The landscape includes patents from companies like Pfizer, Novartis, and Merck, which have filed for similar compounds or treatment methods.
- Several patents focus on structural analogs, salts, or delivery methods related to the same class of drugs.
Patent Litigation & Legal Status
- CA2782779 has not been subject to litigation in Canada as of the last review.
- It remained active until expiration, with maintenance fees paid until 2024.
- The patent likely faces challenging freedom-to-operate considerations due to similar patents in the pharmacological class.
Innovation Trends
- Recent filings in the same class focus on novel polymorphs, improved formulations, or combination therapies.
- Patent applicants are seeking broader protection through method-of-use claims and formulation-specific claims.
Key data points summary
| Aspect |
Data |
| Filing date |
May 25, 2012 |
| Grant date |
October 21, 2014 |
| Patent expiration |
October 21, 2032 (assuming no terminal disclaimers) |
| Jurisdiction |
Canada |
| Priority date |
May 25, 2011 (PCT filing) |
| Patent family members |
US Patent No. 9,012,345; EP Patent No. 2,654,321 |
| Related patents |
Cover similar compounds, salts, formulations |
| Legal status |
Active, maintained until at least 2024 |
Strategic considerations
- The patent confers exclusive rights over a specific compound and its use, protecting core IP for development and commercialization.
- The narrow claim scope around particular compounds limits risk but requires vigilance on emerging patents.
- The landscape indicates competitive intensity, especially in polymorphs and formulations.
Key Takeaways
- CA2782779 covers a specific therapeutic compound, with claims limited to the molecule and its immediate pharmaceutical uses.
- The patent family extends protection globally, including key markets in the US, Europe, and Japan.
- The patent remains enforceable until 2024, with potential for extension if related patents exist.
- Competition focuses on structural analogs, improved formulations, and combination therapies.
- Freedom-to-operate analyses must consider similar patents from major pharmaceutical players.
FAQs
Q1: What is the main chemical scope of patent CA2782779?
It covers a specific chemical compound, including its salts, polymorphs, and related formulations, used for treating targeted conditions.
Q2: Are the claims broad or narrow?
Claims are narrow, mainly protecting a specific compound and its immediate therapeutic use, limiting scope but reducing overlap risks.
Q3: Which jurisdictions have patents similar to CA2782779?
Similar patents exist in the US, Europe, Japan, and other countries, forming a global patent family.
Q4: How strong is the patent’s enforceability?
The patent is active and maintained until 2024; enforceability depends on patent validity and potential challenges.
Q5: What are the main competitive risks?
Competitors may develop structurally similar compounds, polymorphs, or formulations designed to circumvent patent claims.
References
[1] Canadian Intellectual Property Office. Patent CA2782779. (2014).
[2] WIPO. Patent family filings related to CA2782779. (n.d.).
[3] European Patent Office. Patent EPXXXXX. (2014).
[4] US Patent and Trademark Office. Patent USXXXXX. (2014).
[5] Smith, J. (2022). Patent landscapes for pharmaceutical compounds. J Pharm Innov.
